IL4 and lung carcinoma: In addition, with the advent of a new monoclonal (Dupilumab) that blocks the shared receptor for Il-4 and IL-13 used in COPD patients with type 2 inflammation, the inflammation driving both COPD and lung cancer may help prevent the disease [32].